CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC

By afschroeder • August 14, 2025

Lee JM, Pujol JL, Zhang J, Leonov O, Tsuboi M, Kim ES, Ng C, Moreno-Mata N, Cummings A, Hacibekiroglu I, Sehitogullari A, Veeramachaneni N, Spillane C, Duan J, Bossen C, Savchenko A, Lobetti-Bodoni C, Mok T, Garrido P. CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC. JTO Clin Res Rep. 2025 Jun 13;6(8):100859. doi: 10.1016/j.jtocrr.2025.100859. PMID: 40810132; PMCID: PMC12343357.

Tags: Hematology/Oncology, Monoclonal antibodies, neoadjuvant treatment, NSCLC, Publications, Pulmonary, Critical Care & Sleep Medicine

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan[...]

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]